Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspira Women's Health Inc.AWHL · Entity 7871 | Chief Financial Officer | September 02, 2025 | September 04, 2025 |
| Kiromic Biopharma, Inc.KRBP · Entity 87989 | Chief Financial Officer | August 19, 2024 | August 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspira Women's Health Inc.
Report date September 02, 2025 · Filed September 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2035-09-02 | Direct | 100,000 |
Reported balance
After 2025-09-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-09-02 · Grant · Acquired 100,000 · Balance 100,000 F1: 25,000 shares will vest on September 2, 2026. The remaining shares will vest in equal monthly installments over the next 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25,000 shares will vest on September 2, 2026. The remaining shares will vest in equal monthly installments over the next 36 months.
Kiromic Biopharma, Inc.
Report date August 19, 2024 · Filed August 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,933 |
Ending reported balance
After 2024-08-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-19 · Purchase · Acquired 258 · Balance 61,191 Row 2 · 2024-08-20 · Purchase · Acquired 3,742 · Balance 64,933 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 02, 2025 Filed Sep 4, 2025 20:05 UTC | Aspira Women's Health Inc. AWHL · Entity 7871 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001641172-25-026580 · ownership.xml · derivative · entry 1 Hungerford Brian · CIK 0001981345 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-09-02 F1 · derivative.exercise_date: 25,000 shares will vest on September 2, 2026. The remaining shares will vest in equal monthly installments over the next 36 months. Read SEC document |
| August 20, 2024 Filed Aug 21, 2024 16:29 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | PurchaseCommon Stock | 3,742 | $2.20 | $8,221.17 |
DisclosureSEC source: 0001437749-24-027492 · rdgdoc.xml · nonDerivative · entry 2 Hungerford Brian · CIK 0001981345 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,933 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 16:29 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | PurchaseCommon Stock | 258 | $2.25 | $580.50 |
DisclosureSEC source: 0001437749-24-027492 · rdgdoc.xml · nonDerivative · entry 1 Hungerford Brian · CIK 0001981345 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,191 Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 17:03 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | PurchaseCommon Stock | 2,000 | $1.75 | $3,500.00 |
DisclosureSEC source: 0001437749-24-026863 · rdgdoc.xml · nonDerivative · entry 1 Hungerford Brian · CIK 0001981345 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,933 Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 16:30 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | PurchaseCommon Stock | 1,000 | $2.60 | $2,600.00 |
DisclosureSEC source: 0001104659-24-071297 · tm2417214-1_4seq1.xml · nonDerivative · entry 1 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,933 Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 16:36 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | PurchaseCommon Stock | 1,000 | $3.18 | $3,180.00 |
DisclosureSEC source: 0001104659-24-070881 · tm2417108-3_4seq1.xml · nonDerivative · entry 1 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,933 Read SEC document |
| May 03, 2024 Filed May 7, 2024 18:17 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | OtherRestricted Stock Units · Derivative | 21,900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-058167 · tm2413680-2_4seq1.xml · derivative · entry 3 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,900 shares Expires not disclosed F2 · kind: On May 3, 2024, Kiromic BioPharma, Inc. and the Reporting Person agreed to cancel the Reporting Person's 21,900 Restricted Stock Units which vest on October 1, 2024 and replace them with 21,900 Restricted Stock Awards which vest on October 1, 2024. F2 · derivative.exercise_date: On May 3, 2024, Kiromic BioPharma, Inc. and the Reporting Person agreed to cancel the Reporting Person's 21,900 Restricted Stock Units which vest on October 1, 2024 and replace them with 21,900 Restricted Stock Awards which vest on October 1, 2024. F2 · derivative.expiration_date: On May 3, 2024, Kiromic BioPharma, Inc. and the Reporting Person agreed to cancel the Reporting Person's 21,900 Restricted Stock Units which vest on October 1, 2024 and replace them with 21,900 Restricted Stock Awards which vest on October 1, 2024. Read SEC document |
| May 03, 2024 Filed May 7, 2024 18:17 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | GrantRestricted Stock Award | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-058167 · tm2413680-2_4seq1.xml · nonDerivative · entry 2 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,933 F2 · shares: On May 3, 2024, Kiromic BioPharma, Inc. and the Reporting Person agreed to cancel the Reporting Person's 21,900 Restricted Stock Units which vest on October 1, 2024 and replace them with 21,900 Restricted Stock Awards which vest on October 1, 2024. Read SEC document |
| May 03, 2024 Filed May 7, 2024 18:17 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | GrantRestricted Stock Award | 35,033 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-058167 · tm2413680-2_4seq1.xml · nonDerivative · entry 1 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,033 F1 · shares: The Restricted Stock Award vests on April 1, 2025. Read SEC document |
| October 05, 2023 Filed Oct 6, 2023 16:05 UTC | Kiromic Biopharma, Inc. KRBP · Entity 87989 | GrantRestricted Stock Units · Derivative | 21,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-107484 · tm2327977-1_4seq1.xml · derivative · entry 1 Hungerford Brian · CIK 0001981345 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,900 Underlying: Common Stock · 21,900 shares Expires not disclosed F1 · derivative.exercise_price: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. All of the RSUs vest on October 1, 2024 provided that the Reporting Person remains in continuous service on each vesting date. F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. All of the RSUs vest on October 1, 2024 provided that the Reporting Person remains in continuous service on each vesting date. F1 · derivative.expiration_date: The Reporting Person was granted restricted stock units ("RSUs"), which represent a contingent right to receive one share of Common Stock for each RSU. All of the RSUs vest on October 1, 2024 provided that the Reporting Person remains in continuous service on each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.